A Phase I Study in Patients Treated With MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

Trial Profile

A Phase I Study in Patients Treated With MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2018

At a glance

  • Drugs Ferumoxytol (Primary) ; Irinotecan (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Lung cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Ipsen; Merrimack Pharmaceuticals
  • Most Recent Events

    • 26 Jan 2018 Planned End Date changed from 1 Mar 2018 to 1 Jun 2018.
    • 26 Jan 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Jun 2018.
    • 26 Jan 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top